1. Home
  2. BRBR vs PCRX Comparison

BRBR vs PCRX Comparison

Compare BRBR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BellRing Brands Inc.

BRBR

BellRing Brands Inc.

HOLD

Current Price

$8.33

Market Cap

1.0B

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.43

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRBR
PCRX
Founded
2019
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
BRBR
PCRX
Price
$8.33
$23.43
Analyst Decision
Buy
Strong Buy
Analyst Count
17
4
Target Price
$36.63
$30.25
AVG Volume (30 Days)
5.5M
517.6K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
0.65
0.07
Revenue
$2,316,600,000.00
$541,533,000.00
Revenue This Year
$6.28
$6.78
Revenue Next Year
$5.81
$8.54
P/E Ratio
$13.33
$338.29
Revenue Growth
16.05
26.04
52 Week Low
$8.40
$18.80
52 Week High
$63.52
$27.64

Technical Indicators

Market Signals
Indicator
BRBR
PCRX
Relative Strength Index (RSI) 23.61 48.10
Support Level N/A $22.06
Resistance Level $19.23 $24.20
Average True Range (ATR) 0.55 1.04
MACD 0.05 0.05
Stochastic Oscillator 1.31 44.31

Price Performance

Historical Comparison
BRBR
PCRX

About BRBR BellRing Brands Inc.

BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: